Investing.com - Akari Therapeutics (NASDAQ:AKTX) reported on Friday fourth quarter earnings that matched analysts' forecasts and revenue that was inline with expectations.
Akari Therapeutics announced earnings per share of $0.00 on revenue of $0.00. Analysts polled by Investing.com anticipated EPS of $0.00 on revenue of $0.00.
Akari Therapeutics shares are up 1.71% from the beginning of the year, still down 35.97% from its 52 week high of $2.78 set on June 8. They are under-performing the Nasdaq which is up 37.02% from the start of the year.
Akari Therapeutics shares lost 6.32% in intra-day trade following the report.
Akari Therapeutics follows other major Healthcare sector earnings this month
Akari Therapeutics's report follows an earnings beat by Medtronic on November 24, who reported EPS of $1.02 on revenue of $7.65B, compared to forecasts EPS of $0.8033 on revenue of $7.1B.
Zai Lab had matched expectations on December 2 with fourth quarter EPS of $-0.3982 on revenue of $5.2M, compared to forecast for EPS of $-0.3982 on revenue of $5.2M.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar